Bayer, a leading German agrichemical company, announced a return to profitability in the second quarter of 2026, primarily due to a strong performance in its agricultural segment and lower legal costs. Net income reached 219 million euros, marking a significant improvement from the 199 million euro loss recorded in the same period last year.
The Crop Science division, responsible for producing seeds, soybeans, weedkillers, and insecticides, saw core earnings rise by about 30 percent. Conversely, the Pharmaceutical and Consumer Health divisions, which manufacture medications, experienced a slight decline in core earnings. Legal charges linked to litigation costs also decreased from 981 million euros to 172 million euros in the quarter.
Bayer has been embroiled in numerous legal battles since acquiring Monsanto in 2018, leading to the settlement of over 10 billion dollars in cases related to glyphosate-based herbicides. Despite the International Agency for Research on Cancer classifying glyphosate as a probable human carcinogen, Bayer maintains the safety of its products based on scientific studies and regulatory approvals in the US and EU.
In a significant legal victory, Bayer successfully argued before the US Supreme Court that it should be exempt from failure-to-warn claims in US states. The company is now aiming to finalize a $7.25 billion class action settlement, which it believes will conclude the glyphosate litigation saga.
Sales of glyphosate-based herbicides increased by 12.6 percent in the quarter, with particularly strong growth in Europe, the Middle East, and Africa. Bayer's CEO, Bill Anderson, expressed confidence in the company's containment strategy, highlighting important upcoming milestones.
